Despite its immense value, scientific data in chemistry, manufacturing, and controls (CMC) remains largely untapped. As a result, biopharma companies are struggling to accelerate timelines and reduce costs during late-phase development. A group of industry experts explored the root causes and how best to address them. This white paper summarizes their key findings.
Inside, you’ll learn:
- The top 3 business challenges facing CMC and their underlying causes
- Key areas for future development within CMC
- The industry’s readiness for electronic regulatory submissions
- Opportunities for using AI in CMC and their potential impact
